Índice de intervenções por tema

**B. IMAGING -> 03. IMAGING -> 03.1 ECHOCARDIOGRAPHY**

- **PO 121** Prognostic significance of peak atrial longitudinal strain in patients with functional mitral regurgitation
- **PO 122** Identification of high-risk patients with non-ST segment elevation acute coronary syndromes using strain analysis
- **PO 123** Quantitative longitudinal peak systolic strain in the detection of left ventricular wall motion abnormalities: an analysis of our daily echocardiographic practice
- **PO 124** Prognostic value of exercise stress echocardiography in patients with known coronary artery disease
- **PO 125** Mitral regurgitation on low-flow low-gradient severe aortic stenosis and preserved ejection fraction
- **PO 221** Can we count on echocardiography to identify different types of cardiac amyloidosis?
- **PO 222** An echocardiographic insight on post-COVID-19 symptoms.
- **PO 223** Clinical and echocardiographic features of platypnea-orthodeoxia syndrome: a single-centre experience
- **PO 224** Prognostic value of mitral annular plane systolic excursion in patients with acute coronary syndrome and preserved ejection fraction.
- **PO 225** Long term left ventricular impairment after SARS-COV2 infection

**B. IMAGING -> 03. IMAGING -> 03.2 COMPUTED TOMOGRAPHY**

- **PO 2** Association of epicardial fat and coronary artery calcium score in patients with atrial fibrillation
- **PO 3** Gender-specific differences in obstructive coronary artery disease by coronary CT angiography
- **PO 4** Low coronary calcium score in patients with obstructive coronary disease
- **PO 5** Artificial intelligence-enabled comprehensive coronary phenotyping in patients with suspected CAD
- **CO 51** Use of coronary calcium score to refine the cardiovascular risk classification of the new SCORE-2 and SCORE-2 OP algorithms in patients undergoing coronary CT angiography
- **CO 52** Indexing calcium score of the aortic valve to the annulus area improves the grading of aortic stenosis severity in patients within the “grey zone” of aortic valve calcification
B. IMAGING -> 03. IMAGING -> 03.3 CARDIAC MAGNETIC RESONANCE

PO 201  MYOCARDIAL INFARCTION IN THE ABSENCE OF OBSTRUCTIVE CORONARY ARTERY DISEASE - CARDIAC MAGNETIC RESONANCE USE IN IDENTIFYING THE UNDERLYING CAUSES

PO 202  QUANTITATIVE COMPARISON BETWEEN 2D VERSUS 3D LATE GADOLINIUM ENHANCEMENT FOR MYOCARDIAL SCAR CHARACTERIZATION - POSSIBLE IMPLICATION FOR INTERVENTION GUIDANCE AND ARRHHYTHMOGENIC RISK ASSESSMENT

PO 203  LEFT VENTRICULAR MECHANICS IN PATIENTS WITH LEFT BUNDLE BRANCH BLOCK ASSESSED BY CARDIAC MAGNETIC RESONANCE - INFLUENCE OF ETIOLOGY AND PRESENCE OF FIBROSIS

PO 204  VENTRICULAR ARRHYTHMIA IN PATIENTS WITH NORMAL ECHOCARDIOGRAPHY - CAN CARDIOVASCULAR MAGNETIC RESONANCE ENHANCE THE DIAGNOSIS OF STRUCTURAL HEART DISEASE?

CO 53  LATE GADOLINIUM ENHANCEMENT PATTERNS IN SEVERE SYMPTOMATIC HIGH-GRADIENT AORTIC STENOSIS

CO 55  LEFT VENTRICULAR REMODELING IN AORTIC STENOSIS PATIENTS REFERRED FOR SURGICAL AORTIC VALVE REPLACEMENT

CO 132  A CMR MYOCARDIAL STRAIN PATTERNS ANALYSIS IN LEFT BUNDLE BRANCH BLOCK

B. IMAGING -> 03. IMAGING -> 03.4 NUCLEAR IMAGING

PO 1  CARDIAC FAT AND MICROCALCIFICATION AS SURROGATE MARKERS OF CORONARY ATEROGENESIS

PO 205  SEEING BEYOND PERFUSION - IS THERE A ROLE FOR OTHER HIGH-RISK ISCHEMIA MARKERS IN PATIENTS WITH NORMAL PERFUSION ON SPECT MYOCARDIAL PERFUSION IMAGING?

CO 54  99MTC-DPD SCINTIGRAPHY IN THE DIAGNOSIS AND PROGNOSIS OF TRANSTHYRETIN V30M CARDIAC AMYLOIDOSIS

C. ARRHYTHMIAS AND DEVICE THERAPY -> 04. ARRHYTHMIAS, GENERAL -> 04.2 ARRHYTHMIAS, GENERAL - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 92  LONG-TERM PROGNOSIS IN PATIENTS WITH ATRIOVENTRICULAR BLOCK IN ACUTE CORONARY SYNDROME

CO 108  PREVALENCE AND IMPACT OF TACHYARRHYTHMIAS IN PATIENTS ADMITTED WITH COVID-19 PNEUMONIA

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.1 ATRIAL FIBRILLATION - PATHOPHYSIOLOGY AND MECHANISMS

PO 10  AUTONOMIC DYSFUNCTION IS DIVERSE IN REFLEX SYNCOPE AND ATRIAL FIBRILLATION

CO 107  HIGHER CORONARY CALCIUM SCORE IS ASSOCIATED WITH INCREASED RISK OF ATRIAL FIBRILLATION RECURRENTCE

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.2 ATRIAL FIBRILLATION - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 6  BENEFIT OF SLEEP STUDY IN ALL PATIENTS WITH ATRIAL FIBRILLATION AND BMI> 28,0 KG/M2 BEFORE CATHETER ABLATION.

PO 7  ROLE OF EPICARDIAL ADIPOSE TISSUE VOLUME AS PREDICTOR OF ATRIAL FIBRILLATION RECURRENCE

PO 9  X-RAY AF: RESULTADOS PRINCIPAIS DO REGISTO DE FIBRILHAÇÃO AURICULAR EM PORTUGAL CONTINENTAL

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.3 ATRIAL FIBRILLATION - DIAGNOSTIC METHODS

PO 213  SCREENING STRATEGIES FOR ATRIAL FIBRILLATION IN THE ELDERLY POPULATION: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.4 ATRIAL FIBRILLATION - TREATMENT

- PO 8  Evaluating the value of the timing of recurrence during blanking period after atrial fibrillation ablation
- PO 87 Pulmonary vein isolation plus cavotricuspid isthmus ablation shows no benefit in arrhythmia recurrence
- PO 211 Initial experience of atrial fibrillation catheter ablation in a low-volume center: cryoablation vs radiofrequency
- CO 61 Atrial ganglionated plexi modification combined with pulmonary vein isolation in athletes with highly symptomatic atrial fibrillation and baseline bradycardia
- CO 62 Not such a blanking period after all: early recurrence predicts late recurrence after AF ablation
- CO 65 Isolation of pulmonary veins with duty-cycled circular multi-polar catheter

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.5 ATRIAL FIBRILLATION - STROKE PREVENTION

- PO 214 Vitamin-K antagonists versus non-vitamin K oral anticoagulants in elderly patients with severe aortic stenosis and atrial fibrillation

C. ARRHYTHMIAS AND DEVICE THERAPY -> 05. ATRIAL FIBRILLATION -> 05.9 ATRIAL FIBRILLATION - OTHER

- PO 212 Impact of induced atrial fibrillation during atrioventricular nodal reentrant tachycardia ablation

C. ARRHYTHMIAS AND DEVICE THERAPY -> 06. SUPRAVENTRICULAR TACHYCARDIA (NON-AF) -> 06.4 SUPRAVENTRICULAR TACHYCARDIA (NON-AF) - TREATMENT

- CO 63 Fluorolless cavotricuspid isthmus ablation successfully achieves atrial flutter control

C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.2 SYNOPE AND BRADYCARDIA - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

- PO 73 EGSYS score - a useful practice tool for the prediction of reflex syncope?
- PO 94 The applicability of faint score in syncope study and prediction of pacemaker implantation.

C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.4 SYNCOPE AND BRADYCARDIA - TREATMENT

- CO 109 Cardioneuroablation of neurally mediated reflex syncope: the experience of two Portuguese centres

C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.5 SYNCOPE AND BRADYCARDIA - PREVENTION

- PO 75 Impact of a syncope educational prevention program: a first-year experience

C. ARRHYTHMIAS AND DEVICE THERAPY -> 07. SYNCOPE AND BRADYCARDIA -> 07.6 SYNCOPE AND BRADYCARDIA - CLINICAL

- PO 91 Application of syncope guidelines in a center with a trauma-focused triage
C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.2 VENTRICULAR ARRHYTHMIAS AND SCD - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 207 FOLLOW-UP OF SUSTAINED VENTRICULAR TACHYCARDIA IN ACUTE CORONARY SYNDROMES
CO 3 LATE GADOLINIUM ENHANCEMENT IS A STRONG PREDICTOR OF LIFE-THREATENING ARRHYTHMIAS IN PATIENTS WITH NON-ISCHEMIC DILATED CARDIOMYOPATHY UNDERGOING ICD IMPLANTATION FOR PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH
CO 4 IS IT POSSIBLE TO PREDICT MORTALITY AND RECURRENCE OF VT AFTER ABLATION? - PAINESD RISK SCORE APPLICABILITY VS NEW PREDICTORS
CO 110 USEFULNESS OF THE NON-INVASIVE ASSESSMENT OF LATE POTENTIALS FOR RISK STRATIFICATION IN BRUGADA SYNDROME

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.3 VENTRICULAR ARRHYTHMIAS AND SCD - DIAGNOSTIC METHODS

PO 47 THE PERI-INFARCT “GRAY ZONE” OF MYOCARDIAL FIBROSIS IS A BETTER PREDICTOR OF VENTRICULAR ARRHYTHMIAS THAN DENSE CORE FIBROSIS IN PATIENTS WITH PREVIOUS MYOCARDIAL INfarction
PO 49 BRUGADA SYNDROME: CHARACTERIZATION OF A PORTUGUESE BRUGADA SYNDROME COHORT
PO 50 QRS DURATION AND FREQUENT PVC: ADDITIONAL FEATURES IN BRUGADA SYNDROME STRATIFICATION
CO 2 ASSESSMENT OF WAVEFRONT ACTIVATION DURATION ACROSS THE RIGHT VENTRICULAR OUTFLOW TRACT IN PATIENTS WITH IDIOPATHIC PREMATURE VENTRICULAR CONTRACTIONS USING NONINVASIVE ELECTROCARDIOGRAPHIC MAPPING: A VALIDATION STUDY
CO 106 ACCURACY OF NONINVASIVE ELECTROCARDIOGRAPHIC IMAGING USING ISOPOTENTIAL VERSUS ISOCHRONAL MAP FOR IDENTIFYING THE SITE OF ORIGIN OF VENTRICULAR ARRHYTHMIAS.

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.4 VENTRICULAR ARRHYTHMIAS AND SCD - TREATMENT

PO 46 PREDICTORS OF SURVIVAL AND ICD SHOCKS IN NON-ISCHEMIC CARDIOMYOPATHY PATIENTS SUBMITTED TO VENTRICULAR TACHYCARDIA ABLATION
PO 48 CORRELATION BETWEEN LEFT VENTRICLE WALL-THICKNESS BY CT AND ENDOCARDIAL POTENTIALS IN PATIENTS WITH ISCHEMIC CARDIOMYOPATHY - A PILOT STUDY
PO 166 EFFECT OF SACUBITRIL/VALSARTAN ON VENTRICULAR ARRHYTHMIA BURDEN IN HEART FAILURE WITH REDUCED EJECTION FRACTION
PO 206 LONG-TERM IMPACT OF ACTIVATION CIRCUIT-BASED VENTRICULAR TACHYCARDIA ABLATION ON VENTRICULAR ARRHYTHMIA BURDEN
PO 208 EFFICACY OF MEXILETINE IN THE TREATMENT OF PATIENTS WITH RECURRENT VENTRICULAR ARRHYTHMIAS IN LONG-TERM FOLLOW-UP
PO 209 IDIOPATHIC VENTRICULAR ARRHYTHMIA ABLATION - A CENTER EXPERIENCE
PO 210 VENTRICULAR TACHYCARDIA ABLATION IN PATIENTS WITH ISCHAEMIC AND NON-ISCHAEMIC CARDIOMYOPATHY
CO 1 SINUS RHYTHM ENDOCARDIAL MAPPING FOR CHANNELS' IDENTIFICATION IN ISCHEMIC VENTRICULAR TACHYCARDIA USING A MODIFIED ELECTROPHYSIOLOGICAL TRIAD
CO 5 EPICARDIAL MAPPING AS FIRST INTENTION APPROACH FOR STRUCTURAL VENTRICULAR TACHYCARDIA ABLATION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 08. VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH (SCD) -> 08.6 VENTRICULAR ARRHYTHMIAS AND SCD - CLINICAL

PO 169 VENTRICULAR TACHYCARDIA ABLATION IN NON-ISCHEMIC CARDIOMYOPATHY
PO 242 SHANGHAI SCORING SYSTEM FOR RISK STRATIFICATION IN A PORTUGUESE SAMPLE OF BRUGADA SYNDROME PATIENTS
C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.1 ANTIBRADYCARDIA PACING

PO 86 HIS BUNDLE AND LEFT BUNDLE BRANCH PACING: INITIAL EXPERIENCE
PO 90 IMPACT OF THE COVID-19 LOCKDOWN IN EMERGENT PACEMAKER IMPLANTATIONS
PO 244 PREDICTORS OF PACEMAKER DEPENDENCY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
CO 36 PROGNOSTIC IMPACT OF PERCENTAGE OF VENTRICULAR PACING IN PATIENTS REQUIRING PACEMAKER IMPLANTATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
CO 39 PACING VENTRICULAR NA REGIÃO DO RAMO ESQUERDO - EXPERIÊNCIA INICIAL

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.2 IMPLANTABLE CARDIOVERTER / DEFIBRILLATOR

PO 95 SAFETY OF SAME-DAY VS NEXT-DAY DISCHARGE AFTER CIED: A SINGLE-CENTER EXPERIENCE
PO 168 THE EFFECTS OF SACUBITRIL-VALSARTAN ON ICD INDICATION IN PATIENTS WITH HEART FAILURE
PO 170 PRIMARY PREVENTION IMPLANTATION OF CARDIOVERTER DEFIBRILLATORS IN TRULY ASYMPTOMATIC PATIENTS - SHOULD WE RETHINK CURRENT RECOMMENDATIONS?
CO 37 HEART RATE SCORE: A SIMPLE AND USEFUL PREDICTOR FOR CLINICAL OUTCOMES IN HEART FAILURE

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.3 CARDIAC RESYNCHRONIZATION THERAPY

PO 93 LOWER RATE LIMIT IN CARDIAC RESYNCHRONIZATION THERAPY-DEFIBRILLATORS: IS LOWER BETTER?
CO 38 WHAT IS THERE TO EAARN WITH A CRT IMPLANTATION? PREDICTIVE FACTORS OF MORTALITY OR CLINICAL DETERIORATION IN PATIENTS RECEIVING CARDIAC RESYNCHRONIZATION THERAPY BASED ON PRE-IMPLANT FACTORS.
CO 40 APICAL VERSUS SEPTAL PACING AND UPGRADE TO CARDIAC RESYNCHRONIZATION THERAPY: WHAT ARE THE ODDS?

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.4 HOME AND REMOTE PATIENT MONITORING

PO 167 TELEMONITORING IN HEART FAILURE MANAGEMENT - THE EXPERIENCE OF A REMOTE CENTER
PO 215 RESPIRATORY DISTURBANCE INDEX AS A PREDICTOR OF ATRIAL FIBRILLATION

C. ARRHYTHMIAS AND DEVICE THERAPY -> 09. DEVICE THERAPY -> 09.6 DEVICE THERAPY - OTHER

PO 88 USEFULNESS OF THE PHYSIOLOGICAL VDD PACEMAKER IN ELDERLY PATIENTS WITH NORMAL SINUS RHYTHM
PO 89 ACESSO VENOSO AXILAR PARA IMPLANTAÇÃO DE DISPOSITIVOS DE PACING - EXPERIÊNCIA DE UM CENTRO

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.2 CHRONIC HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 18 HEART FAILURE- ONE ONLY DISEASE OR A GROUP OF DIFFERENT ENTITIES?
PO 19 HEART-KIDNEY CROSSTALK: HEART FAILURE AND THE RISK OF CARDIOVASCULAR EVENTS AND END STAGE RENAL DISEASE IN YOUNG TYPE 2 DIABETIC PATIENTS
PO 59 HEMODYNAMIC GAIN INDEX: A NEW PROGNOSTIC MARKER IN HEART FAILURE?
PO 60 THE HFFI, A NEW FRAILTY INDEX FOR ASSESSING LONG-TERM OUTCOMES IN HEART FAILURE
PO 100 THE NEED FOR DIURETIC THERAPY IN SPITE OF HEART FAILURE WITH REDUCED EJECTION FRACTION FOUNDATIONAL THERAPY: A NEW MARKER OF ADVERSE PROGNOSIS?
PO 139  PROGNOSTIC IMPACT OF RIGHT VENTRICULAR FUNCTION IN ADVANCED HEART FAILURE
PO 140  FUNCTIONAL MITRAL REGURGITATION IN ADVANCED HEART FAILURE
PO 176  HYPERKALEMIA AND HEART FAILURE WITH REDUCED EJECTION FRACTION: PREVALENCE AND PROGNOSTIC IMPACT ON A PORTUGUESE POPULATION
PO 179  HIGH PREVALENCE OF POLYCYTHEMIA IN HEART FAILURE PATIENTS
PO 217  IMPACT OF SGLT2 INHIBITORS ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
CO 98  SACUBITRIL-VALSARTAN VERSUS ACEI IN LEFT VENTRICULAR REVERSE REMODELLING AND CARDIOVASCULAR OUTCOMES
CO 127  I NEED HELP: FROM THE ACRONYM TO THE RISK SCORE FOR PREDICTING ADVERSE OUTCOMES IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
CO 128  CARDIORENAL SYNDROME AND DEATH RISK IN PATIENTS WITH HEART FAILURE OR CHRONIC KIDNEY DISEASE: AN UNMET CARDIORENAL NEED?
CO 129  EXERCISE OSCILLATORY VENTILATION - IS THERE MORE TO IT THAN JUST UPS AND DOWNS?

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.3 CHRONIC HEART FAILURE - DIAGNOSTIC METHODS
PO 20   LEFT BUNDLE BRANCH BLOCK - IS IT POSSIBLE TO PREDICT LEFT VENTRICLE DYSFUNCTION?
PO 137  EVALUATION OF RV-ARTERIAL COUPLING IN ADVANCED HEART FAILURE
CO 47   BNP VERSUS NT-PROBNP FOR ECHOCARDIOGRAPHIC AND HEMODYNAMIC PARAMETERS PREDICTION IN HEART TRANSPLANTED PATIENTS
CO 49   CAN ECHOCARDIOGRAPHIC PARAMETERS EFFECTIVELY PREDICT ELEVATED PCWP IN HEART TRANSPLANT PATIENTS?
CO 57   ONLY RIGHT VENTRICULAR FUNCTION PARAMETERS CAN PREDICT ACUTE CELLULAR REJECTION IN HEART TRANSPLANT PATIENTS?

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.4 CHRONIC HEART FAILURE - TREATMENT
PO 16   CLINICAL DETERMINANTS AND BARRIERS TO CARDIAC REHABILITATION ENROLMENT OF HEART FAILURE PATIENTS
PO 96   LEVOSIMENDAN IN OUTPATIENTS WITH ADVANCED HEART FAILURE: SINGLE-CENTER EXPERIENCE OF 200 INTERMITENT PERFUSIONS
PO 97   SACUBITRIL-VALSARTAN: THE EARLIER, THE BETTER?
PO 98   PREDICTORS OF SACUBITRIL-VALSARTAN TARGET DOSE ACHIEVEMENT IN A REAL-WORLD POPULATION
PO 99   MAXIMUM DOSE SACUBITRIL/VALSARTAN IN THE ELDERLY PEOPLE WITH HEART FAILURE AND REDUCED EJECTION FRACTION.
PO 138  RESPONSE AND LONG-TERM OUTCOMES WITH RESYNCHRONIZATION THERAPY: DOES HEART FAILURE ETIOLOGY MATTER?
PO 216  DAPAGLIFLOZIN IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A RANDOMIZED CONTROLLED TRIAL
PO 218  SGLT2 INHIBITORS IN HEART FAILURE WITH REDUCED EJECTION FRACTION: THEIR BIOLOGICAL PROPERTIES GOES WELL BEYOND A SMART DIURETIC EFFECT
PO 219  SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS: THE GLUE FOR HEART FAILURE WITH REDUCED EJECTION FRACTION FOUNDATIONAL THERAPY
PO 220  DAPAGLIFLOZIN IN THE REAL WORLD - WHAT IS THE IMPACT ON HEART FAILURE WITH REDUCED EJECTION FRACTION ALREADY UNDER OPTIMIZED THERAPY?
CO 56   CARDIAC RESYNCHRONIZATION THERAPY IN ATRIAL FIBRILLATION: RESPONSE AND LONG-TERM OUTCOMES
CO 58   THE EFFECT OF HEART FAILURE THERAPY IN PATIENTS WITH MILDLY REDUCED EJECTION FRACTION: A NETWORK META-ANALYSIS
CO 59   HEART FAILURE WITH REDUCED EJECTION FRACTION FOUNDATIONAL THERAPY: WHY SHOULD WE FOLLOW THE 2021 EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE GUIDELINES AND FORGET THE PREVIOUS THERAPEUTIC ALGORITHM?
CO 60 MAIN LIMITING FACTORS OF FOUNDATIONAL THERAPY INTRODUCTION IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
CO 96 LEFT VENTRICULAR STRAIN IMAGING IN HEART FAILURE PATIENTS UNDER SACUBITRIL/VALSARTAN THERAPY
CO 97 SAFETY AND EFFECTIVENESS OF SACUBITRIL-VALSARTAN IN A REAL-WORLD POPULATION

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.5 CHRONIC HEART FAILURE - PREVENTION
PO 177 SERUM URIC ACID LEVELS PROGNOSTIC VALUE IN CHRONIC HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION
CO 46 REMOTE INVASIVE MONITORING OF PULMONARY ARTERY PRESSURE IN PATIENTS WITH HEART FAILURE: INITIAL EXPERIENCE OF A TERTIARY CARE CENTER
CO 99 DOES DAPAGLIFLOZIN IMPROVE CARDIOPULMONARY PERFORMANCE OF NON-DIABETIC HEART FAILURE PATIENTS?

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.6 CHRONIC HEART FAILURE - CLINICAL
PO 17 PHYSICAL ACTIVITY AND HEART FAILURE: A FORGOTTEN INDICATOR
CO 48 NT-PROBNP FOR FUNCTIONAL CAPACITY ASSESSMENT IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
CO 126 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: A 2-YEAR SINGLE-CENTRE EXPERIENCE

D. HEART FAILURE -> 10. CHRONIC HEART FAILURE -> 10.7 CHRONIC HEART FAILURE - OTHER
CO 50 LONG-TERM BENEFITS OF NON-INVASIVE TELEMONITORING IN PATIENTS WITH CHRONIC HEART FAILURE

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.2 ACUTE HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME
PO 56 DOES BLOOD UREA NITROGEN-TO-CREATININE RATIO PREDICT OUTCOMES IN DECOMPENSATED HEART FAILURE?
PO 57 CHEST SCORE - HEART FAILURE RISK SCORE: PREDICTIVE VALUE FOR ONE-YEAR MORTALITY AND RE-ADMISSION AFTER DISCHARGE
PO 58 GWTG-HF SCORE VS AHEAD SCORE: WHICH SCORES BETTER?
CO 100 SGLT2 INHIBITOR INITIATION IN PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: DOES IT STILL MATTER WHEN PATIENTS ARE STRICTLY FOLLOWED AFTER DISCHARGE?
CO 130 MODIFIED VERSUS CONVENTIONAL BODY MASS INDEX IN PATIENTS ADMITTED DUE TO ACUTE HEART FAILURE: ASSOCIATION WITH ADVERSE PROGNOSIS.

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.3 ACUTE HEART FAILURE - DIAGNOSTIC METHODS
PO 178 IRON STATUS VARIATION IN ACUTE HEART FAILURE: A PROSPECTIVE STUDY - RELEASE OF PRELIMINARY DATA

D. HEART FAILURE -> 11. ACUTE HEART FAILURE -> 11.6 ACUTE HEART FAILURE - CLINICAL
PO 136 PATIENTS ADMITTED WITH ACUTE HEART FAILURE AT AN INTENSIVE CARE DEPARTMENT - COMPARISON BETWEEN THE CLINICAL PROFILES OF PATIENTS WITH PRESERVED VS. REDUCED LEFT VENTRICULAR EJECTION FRACTION
PO 180 PLASMA VOLUME VARIATION AND GLOMERULAR FILTRATION RATE IN HEART FAILURE ADMISSIONS
E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.2 CORONARY ARTERY DISEASE - EPIDEMIOLOGY,
PROGNOSIS, OUTCOME
PO 27 RELATIONSHIP BETWEEN THE BLOOD PRESSURE AND THE LONG-TERM PROGNOSIS IN A COHORT OF CORONARY
PATIENTS
PO 28 LIPOPROTEIN(A) AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CORONARY ARTERY DISEASE AND IMPAIRED
GLUCOSE METABOLISM
CO 89 WORKLOAD-INDEXED BLOOD PRESSURE RESPONSE PREDICTS CARDIOVASCULAR EVENTS IN CORONARY ARTERY DISEASE

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.3 CORONARY ARTERY DISEASE - DIAGNOSTIC
METHODS
PO 29 MY PATIENT HAS A POSITIVE ISCHEMIA TEST: WILL HE HAVE OBSTRUCTIVE CORONARY ARTERY DISEASE?
PO 30 EXERCISE ELECTROCARDIOGRAM - A DIAGNOSTIC TEST OF THE PAST?

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.4 CORONARY ARTERY DISEASE - TREATMENT
CO 27 CORONARY SINUS REDUCER DEVICE FOR THE TREATMENT OF REFRACTORY ANGINA THERAPY. A MULTICENTRIC INITIAL
EXPERIENCE.

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.5 CORONARY ARTERY DISEASE - PREVENTION
PO 26 COMPARISON BETWEEN THE EUROPEAN SCORE AND THE UPDATED SCORE2 FOR CARDIOVASCULAR OUTCOMES

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
12. CORONARY ARTERY DISEASE (CHRONIC) -> 12.6 CORONARY ARTERY DISEASE - CLINICAL
PO 186 CHRONOTROPIC INCOMPETENCE - STILL A SUITABLE INDICATOR?

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
13. ACUTE CORONARY SYNDROMES -> 13.1 ACUTE CORONARY SYNDROMES - PATHOPHYSIOLOGY
AND MECHANISMS
CO 29 CIRCADIAN RHYTHM IMPACT IN REMOTE ISCHEMIC CONDITIONING IN MYOCARDIAL INFARCTION

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->
13. ACUTE CORONARY SYNDROMES -> 13.2 ACUTE CORONARY SYNDROMES - EPIDEMIOLOGY,
PROGNOSIS, OUTCOME
PO 32 HOW MUCH MORE HYPERGLYCEMIC IS MY MYOCARDIAL INFARCTION PATIENT AND WHY DOES IT MATTER?
PO 43 OUTCOMES OF PATIENTS WITH ACUTE UNPROTECTED LEFT MAIN CORONARY OCCLUSION: A MULTICENTRE STUDY
PO 44 ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE OCCLUSION OF THE LEFT MAIN CORONARY ARTERY - DOES
AGE MATTER?
PO 70 UTILITY OF THE AGE SHOCK INDEX IN PATIENTS WITH AN ACUTE CORONARY SYNDROME
PO 108 CORONARY RESTENOSIS: SEVENTEEN YEARS SUMMARIZED...
PO 109 DELAY BETWEEN SYMPTOMS ONSET AND SEEKING MEDICAL CARE - DOES INITIAL RHYTHM PLAYS A ROLE?
PO 110 SHOULD WE STAY OR SHOULD WE GO: ASSESSMENT OF THE NEED FOR THE IMPLANTATION OF A DEFINITE PACEMAKER IN A POPULATION OF ACUTE CORONARY SYNDROME THAT EVOLVED IN ADVANCED ATRIOVENTRICULAR BLOCK.

PO 149 THE OBESITY PARADOX IN ACUTE ST-ELEVATED MYOCARDIAL INFARCTION

PO 150 IS SYMPTOMS-BALLOON-TIME A BETTER PROGNOSTIC PREDICTOR?

PO 161 CHARACTERIZATION OF RISK FACTORS AND MORTALITY IN YOUNG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

PO 162 GENDER DISPARITIES IN ACUTE MYOCARDIAL INFARCTION - STILL AN UNSOLVED PUZZLING ISSUE

PO 163 MACE IN MYOCARDIAL INFARCTION WITH NON-OBSTRUCTIVE CORONARY ARTERIES: PREDICTORS AND PROGNOSIS

PO 164 DISCRIMINATORY CAPACITY OF ACTION-ICU ACCORDING TO AGE - A SCORE FOR ALL?

PO 187 ACUTE KIDNEY INJURY ON ADMISSION FOR ACUTE CORONARY SYNDROME AS A PREDICTOR OF 1-YEAR MORTALITY

PO 189 C-REACTIVE PROTEIN AS A PROGNOSTIC MARKER IN MYOCARDIAL INFARCTION WITH NON-OBSTRUCTIVE CORONARY ARTERIES

CO 7 STEMI WITH MID-RANGE EJECTION FRACTION - A GROUP OF INTERMEDIATE RISK NOT TO BE FORGOTTEN

CO 8 PRECISE-DAPT SCORE FOR BLEEDING PREDICTION AFTER ACUTE CORONARY SYNDROME IN PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION FOR MULTIVESSEL DISEASE

CO 9 RESUSCITATED CARDIAC ARREST IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION IS ASSOCIATED WITH INCREASED INFARCT SIZE AND WORSE OUTCOMES

CO 68 ACUTE TOTAL OCCLUSION OF THE UNPROTECTED LEFT MAIN CORONARY ARTERY - PATIENT CHARACTERISTICS AND OUTCOMES

CO 69 MECHANICAL CIRCULATORY SUPPORT DEVICES IN LEFT MAIN OCCLUSION: A MULTICENTER STUDY FROM 2008 TO 2020

CO 70 AMI DUE TO LEFT MAIN CORONARY ARTERY OCCLUSION: A COMPARATIVE MULTICENTER STUDY FROM 2008 TO 2020

CO 87 NEW-ONSET OF ATRIAL FIBRILLATION IN ST-ELEVATION MYOCARDIAL INFARCTION

CO 88 FUNCTIONAL IRON DEFICIENCY IN ACUTE CORONARY SYNDROMES: PREVALENCE AND PROGNOSTIC IMPACT

CO 90 LONG-TERM PROGNOSIS OF MYOCARDIAL INFARCTION WITH NON-OBSTRUCTIVE CORONARY ARTERIES VERSUS MYOCARDIAL INFARCTION WITH OBSTRUCTIVE CORONARY ARTERY DISEASE

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->

13. ACUTE CORONARY SYNDROMES --> 13.3 ACUTE CORONARY SYNDROMES - DIAGNOSTIC METHODS

PO 165 FINDING TAKOTSUBO CARDIOMYOPATHY ON CARDIAC MAGNETIC RESONANCE

PO 190 PERFORMANCE OF DIFFERENT HIGH SENSITIVITY CARDiac TROPONIN ASSAYS IN PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROME

CO 72 TÉCNICOS DE CARDIOPNEUMOLOGIA NO SERVIÇO DE URGÊNCIA NA PRESTAÇÃO DE CUIDADOS AOS DOENTES COM SÍNDROME CORONÁRIA AGUDA

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE ->

13. ACUTE CORONARY SYNDROMES --> 13.4 ACUTE CORONARY SYNDROMES - TREATMENT

PO 45 EMERGENT CORONARY ANGIOGRAPHY IN A 90-PLUS POPULATION - OUTCOMES AT 5-YEARS FOLLOW-UP

PO 66 CABG VS PCI FOR DIABETIC PATIENTS WITH NON-ST ELEVATION ACS: IN-HOSPITAL OUTCOMES

PO 67 CABG VS PCI FOR DIABETIC PATIENTS WITH NON-ST ELEVATION ACS: ONE-YEAR OUTCOMES

PO 69 BLEEDING RISK IN PATIENTS WITH NSTEMI: P2Y12 INHIBITORS PRESCRIPTION PATTERNS FROM 2019 TO 2021

PO 146 THE IMPACT OF OUTPATIENT EMERGENCY MEDICAL SYSTEM IN STEMI PATIENTS UNDERGOING PRIMARY ANGIOPLASTY: A SINGLE-CENTRE EXPERIENCE

PO 147 AT THE OUTER EDGE OF STEMI TIME: EVEN AFTER 12 HOURS, THE CLOCK KEEPS TICKING.

PO 148 STEMI TREATMENT IN REMOTE LOCATIONS: AN UNCOMMON REALITY

CO 10 SGLT2 INHIBITION IN ACUTE MYOCARDIAL INFARCTION WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION

CO 30 EFFECTIVENESS AND SAFETY OF P2Y12 INHIBITOR PRETREATMENT FOR PRIMARY PCI IN STEMI: SYSTEMATIC REVIEW AND META-ANALYSIS
E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 13. ACUTE CORONARY SYNDROMES -> 13.5 ACUTE CORONARY SYNDROMES - PREVENTION

PO 107  DO PATIENTS WITH CARDIOVASCULAR RISK FACTORS REALIZE WHAT IS AT RISK?

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 13. ACUTE CORONARY SYNDROMES -> 13.6 ACUTE CORONARY SYNDROMES - CLINICAL

PO 42  A MULTICENTER REGISTRY OF ACUTE LEFT MAIN CORONARY ARTERY OCCLUSION: DIABETES MATTERS?
PO 68  SYMPTOMS AT NSTEMI PRESENTATION: DO PATIENT’S COMPLAINTS PREDICT THE OUTCOME?
PO 106  PHYSICAL EXERCISE ACTIVITY TRENDS IN ACUTE MYOCARDIAL INFARCTION PATIENTS - WHERE DO WE STAND?
CO 6  ACUTE MYOCARDIAL INFARCTION DURING COVID-19 ERA: PATIENT CHARACTERISTICS, PRESENTATION AND OUTCOMES
CO 86  CORRELATION BETWEEN NSTE-ACS RISK SCORES WITH SYNTAX: CAN WE PREDICT CORONARY LESION COMPLEXITY BEFORE ANGIOGRAPHY?

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 14. ACUTE CARDIAC CARE -> 14.2 ACUTE CARDIAC CARE - PREHOSPITAL AND EMERGENCY DEPARTMENT CARE

PO 188  MODIFIED M-CHA2DS2-VASC SCORE PREDICTS MORTALITY AT EMERGENCY DEPARTMENT ADMISSION IN COVID-19 PATIENTS
CO 26  PATIENT DELAY IN ACUTE MYOCARDIAL INFARCTION - A LONG JOURNEY STILL AHEAD

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 14. ACUTE CARDIAC CARE -> 14.3 ACUTE CARDIAC CARE - CCU, INTENSIVE, AND CRITICAL CARDIOVASCULAR CARE

PO 41  MANAGEMENT OF ACUTE LEFT MAIN OCCLUSION IN SURGICAL AND NON-SURGICAL CENTERS: A MULTICENTER STUDY

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 14. ACUTE CARDIAC CARE -> 14.4 ACUTE CARDIAC CARE - CARDIOGENIC SHOCK

CO 28  PERIPHERAL VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION FOR REFRACTORY CARDIOGENIC SHOCK: SINGLE-CENTER EXPERIENCE
CO 66  CARDIOGENIC SHOCK COMPLICATING ACUTE MYOCARDIAL INFARCTION DUE TO LEFT MAIN CORONARY ARTERY OCCLUSION: A MULTICENTRE STUDY

E. CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE -> 14. ACUTE CARDIAC CARE -> 14.5 ACUTE CARDIAC CARE - CARDIAC ARREST

CO 67  CARDIAC ARREST IN PATIENTS WITH ACUTE LEFT MAIN STEM OCCLUSION: A REAL-WORLD MULTICENTER REGISTRY

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 15. VALVULAR HEART DISEASE -> 15.1 VALVULAR HEART DISEASE - PATHOPHYSIOLOGY AND MECHANISMS

PO 79  LEFT VENTRICULAR REVERSE REMODELING IN POST OPERATIVE AORTIC STENOSIS PATIENTS: PREVALENCE AND PREDICTOR(S)
F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.2 VALVULAR HEART DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 36 TRICUSPID REGURGITATION - PATIENTS CHARACTERISTICS, TREATMENT AND OUTCOMES
PO 37 IMPACT OF CONCOMITANT MITRAL AND TRICUSPID REGURGITATION IN PATIENTS WITH SIGNIFICANT CHRONIC AORTIC REGURGITATION
PO 80 SHOULD CONTRACTILE RESERVE BE A DECISIVE FACTOR ON SEVERE AORTIC VALVE INTERVENTION?
PO 117 AORTIC STENOSIS - THE LUNG IS OFTEN OVERLOADED, BUT WHAT ABOUT THE LIVER?
PO 118 AORTIC VALVE CALCIUM SCORE AND PERI-PROTHESIS LEAKS AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: IS THERE A HINT?
PO 120 PREVALENCE, MANAGEMENT, AND PROGNOSIS OF PATIENTS WITH SEVERE AORTIC STENOSIS AND REDUCED EJECTION FRACTION
CO 15 CONTRACTILE RESERVE: A KEY FACTOR IN AORTIC STENOSIS
CO 94 FUNCTIONAL MITRAL REGURGITATION: KEEPING COHERENCE WITH THE ASE GRADING GUIDELINES, WHICH PROPORTIONALITY CONCEPT BEST PREDICTS PROGNOSIS IN THE REAL WORLD?

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.3 VALVULAR HEART DISEASE - DIAGNOSTIC METHODS

PO 76 IS FLOW BETTER IN ML/M2 OR ML/S - A PRACTICAL REFLECTION ON AORTIC STENOSIS
PO 116 NORMAL FLOW, LOW GRADIENT AORTIC STENOSIS - IS LVOT THE DETERMINANT?
CO 12 A PRELIMINARY ANALYSIS REGARDING FUNCTIONAL MITRAL REGURGITATION GRADING WITH ECHOCARDIOGRAPHY AND CMR: IN SEARCH OF SIMILARITIES AND RESOLVING DISCORDANCES.
CO 144 DOES MY TAVR PATIENT HAVE CARDIAC AMYLOIDOSIS?

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.4 VALVULAR HEART DISEASE - TREATMENT

PO 38 CLINICAL AND ECHOCARDIOGRAPHIC PREDICTORS OF WORSENING MITRAL REGURGITATION AFTER PERCUTANEOUS MITRAL VALVE REPAIR
PO 39 COVID-19 IMPACT ON REFERRALS, TREATMENT DECISIONS AND TIME ON THE WAITING LIST FOR VALVULAR HEART DISEASE INTERVENTION
PO 40 IS WILKINS SCORE OVER 9 A DEFINITIVE LIMIT TO FAVORABLE LONG-TERM SUCCESS IN PERCUTANEOUS VALVE COMMISSUROTOMY?
PO 78 FLOW RATE IN SEVERE AORTIC STENOSIS - A GOOD PROGNOSTIC MARKER FOR PERCUTANEOUS VALVE IMPLANTATION?
PO 119 TAVI - MULTIDIMENSIONAL EARLY BENEFITS ON ELDERLY PATIENTS
CO 13 CLINICAL AND ECHOCARDIOGRAPHIC VERY LONG-TERM OUTCOMES AFTER PERCUTANEOUS MITRAL BALLOON VALVULOPLASTY IN SEVERE RHEUMATIC MITRAL STENOSIS
CO 14 PERCUTANEOUS VALVE COMMISSUROTOMY FOR MITRAL STENOSIS PATIENTS: A 20 YEARS FOLLOW-UP
CO 92 TRANSCATHETER AORTIC VALVE IMPLANTATION OUTCOMES IN PATIENTS WITH LOW FLOW - LOW GRADIENT AORTIC STENOSIS
CO 146 BIOLOGICAL OR MECHANICAL AORTIC PROSTHESES IN PATIENTS AGED 40-60 YEARS: A SINGLE CENTRE EXPERIENCE

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.6 VALVULAR HEART DISEASE - CLINICAL

PO 25 ELECTROCARDIOGRAPHIC ASSESSMENT OF LVH IN AORTIC STENOSIS PATIENTS: HOW WELL DOES IT CORRELATE WITH MYOCARDIAL MASS?
F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
15. VALVULAR HEART DISEASE -> 15.7 VALVULAR HEART DISEASE - OTHER
PO 77  LEFT VENTRICULAR REVERSE REMODELING AFTER TAVR FOR AORTIC STENOSIS
CO 11  REVERSE LEFT VENTRICULAR REMODELING AFTER AORTIC VALVE REPLACEMENT FOR AORTIC STENOSIS: SYSTEMATIC REVIEW AND META-ANALYSIS

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
16. INFECTIVE ENDOCARDITIS -> 16.2 INFECTIVE ENDOCARDITIS - EPIDEMIOLOGY, PROGNOSIS, OUTCOME
PO 196  ENDOCARDITIS IN-HOSPITAL MORTALITY: WHAT CAN WE EXPECT?
PO 198  INFECTIVE ENDOCARDITIS: HAS ITS PROGNOSIS CHANGED 5 YEARS AFTER THE NEW ESC GUIDELINES?
PO 199  PREDICTORS OF IN-HOSPITAL MORTALITY IN INFECTIOUS ENDOCARDITIS
PO 200  PREDICTORS OF RECURRENCE IN INFECTIOUS ENDOCARDITIS

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
16. INFECTIVE ENDOCARDITIS -> 16.6 INFECTIVE ENDOCARDITIS - CLINICAL
PO 33  SHOULD WE TRUST SCORES TO RULE OUT TRANSESOPHAGIC ECHOCARDIOGRAPHY IN PATIENTS WITH STAPHYLOCOCCUS AUREUS BACTERIEMIA?
PO 197  INFECTIVE ENDOCARDITIS: EXPERIENCE OF THE LAST 20 YEARS

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.1 MYOCARDIAL DISEASE - PATHOPHYSIOLOGY AND MECHANISMS
PO 127  CHRONOTROPIC INCOMPETENCE AND ITS RELATION TO EXERCISE CAPACITY IN HYPERTROPHIC CARDIOMYOPATHY

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.2 MYOCARDIAL DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME
PO 34  CARDIAC MAGNETIC RESONANCE IN MYOCARDITIS: BESIDES THE DIAGNOSIS?
PO 35  IMPLICATIONS OF SEPTAL LATE Gadolinium ENHANCEMENT IN PATIENTS WITH ACUTE MYOCARDITIS
PO 126  RELATIVE APICAL LONGITUDINAL STRAIN - A POWERFUL TOOL TO PREDICT LONG-TERM OUTCOMES IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY PATIENTS
PO 171  PREDICTORS OF IN-HOSPITAL LEFT VENTRICLE FUNCTION RECOVERY IN TAKOTSUBO SYNDROME
PO 173  TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM): A POTENTIAL ROLE FOR CARDIOPULMONARY EXERCISE TESTING
PO 175  SPONGY MYOCARDIUM OR LEFT VENTRICULAR NONCOMPACITION: WHICH FACTORS IMPACT PROGNOSIS?
CO 114  MYOCARDIAL DEFORMATION ANALYSIS USING CARDIAC MAGNETIC RESONANCE IN APICAL HYPERTROPHIC CARDIOMYOPATHY
CO 115  REDUCED 3D-LEFT ATRIUM EJECTION FRACTION PREDICTS DEVELOPMENT OF ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
CO 142  MECHANICAL DISPERSION: CAN IT PREDICT THE OCCURRENCE OF VENTRICULAR ARRHYTHMIAS IN FABRY DISEASE?
CO 143  CLINICAL AND ECHOCARDIOGRAPHIC PROGNOSTIC FACTORS IN WILD TYPE TRANSTHYRETIN CARDIAC AMYLOIDOSIS

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.3 MYOCARDIAL DISEASE - DIAGNOSTIC METHODS
PO 128  COMPARISON OF LEFT VENTRICULAR STRAIN OBTAIN BY CARDIAC MAGNETIC RESONANCE 3D FEATURE TRACKING AND 3D SPECKLE TRACKING ECHOCARDIOGRAPHY, IN HYPERTROPHIC CARDIOMYOPATHY
PO 129 CORONARY FLOW VELOCITY RESERVE IN HYPERTROPHIC CARDIOMYOPATHY: RELATION WITH NONUNIFORM MYOCARDIAL HYPERTROPHY

PO 130 SIGNALLING AMYLOIDOSIS DIAGNOSIS WITH RED FLAGS

PO 174 TRANSTHYRETIN CARDIAC AMYLOIDOSIS DUE TO RARE MUTATIONS IN PORTUGUESE PATIENTS

CO 91 SEGMENTAL ANALYSIS OF MICROVASCULAR DYSFUNCTION AND TISSUE CHARACTERIZATION IN HYPERTROPHIC CARDIOMYOPATHY BY MAGNETIC RESONANCE IMAGING

CO 112 THREE DIMENSIONAL MYOCARDIAL DEFORMATION PARAMETERS ARE ASSOCIATED WITH FUNCTIONAL CAPACITY IN HYPERTROPHIC CARDIOMYOPATHY

CO 113 MICROVASCULAR DYSFUNCTION IS ASSOCIATED WITH IMPAIRED MYOCARDIAL WORK IN OBSTRUCTIVE AND NONOBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: A MULTIMODALITY APPROACH

CO 141 MICROVASCULAR DYSFUNCTION AND MYOCARDIAL FIBROSIS IMPACT ON LEFT VENTRICULAR MYOCARDIAL DEFORMATION IN HYPERTROPHIC CARDIOMYOPATHY - PER SEGMENT ANALYSIS BY MAGNETIC RESONANCE IMAGING

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.4 MYOCARDIAL DISEASE - TREATMENT

CO 111 ECHOCARDIOGRAPHIC OUTCOMES OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY AFTER PERCUTANEOUS ASA: A SINGLE CENTRE EXPERIENCE

CO 147 MIECTOMIA MORROW NA MIOCARDIOPATIA HIPÉRÔFICA OBSTRUTIVA: RESULTADOS A CURTO E LONGO PRAZO DE UM CENTRO REFERÊNCIA

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.6 MYOCARDIAL DISEASE - CLINICAL

CO 145 MYOCARDITIS, PERICARDITIS AND COVID-19 VACCINATION - A TRUE CONCERN?

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
17. MYOCARDIAL DISEASE -> 17.7 MYOCARDIAL DISEASE - OTHER

PO 172 TAKOTSUBO SYNDROME: TEN-YEAR EXPERIENCE FROM A SINGLE CENTER

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
19. TUMORS OF THE HEART -> 19.3 TUMORS OF THE HEART - DIAGNOSTIC METHODS

PO 61 PAPILLARY FIBROELASTOMAS - DIAGNOSTIC CHALLENGES AND CLINICAL AND MORPHOLOGIC FEATURES

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->

PO 62 CARDIAC MYXOMA EMBOLIC EVENTS: CHARACTERIZATION AND PREDICTORS

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE ->
20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.2 CONGENITAL HEART DISEASE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 82 OPTIMIZING ADULT CONGENITAL HEART DISEASE CARE: EXPERIENCE OF AN ORGANIZED PROGRAM IN A REMOTE NON SPECIALIST CENTER

PO 84 LONG-TERM OUTCOME IN FONTAN PROCEDURE PATIENTS: THE DESTINATION THERAPY OR A BRIDGE TO TRANSPLANT?

CO 116 PREGNANCY OUTCOMES IN WOMEN WITH SEVERE CONGENITAL HEART DISEASE - A SPECIALIZED CENTRE EXPERIENCE

CO 117 IMPACT OF COVID-19 IN ADULT PATIENTS WITH CONGENITAL HEART DISEASE
Índice de intervenções por tema

CO 120  THE WORLD UPSIDE DOWN - AFTER 20 YEARS FOLLOW-UP OF DEXTRO-TRANSPOSITION OF THE GREAT ARTERIES
CO 140  CARDIOPULMONARY EXERCISE TESTING IN REPAIRED TETRALOGY OF FALLOT AND RIGHT VENTRICLE DILATATION

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.4 CONGENITAL HEART DISEASE - TREATMENT

PO 81  NOAC IN ADULT CONGENITAL HEART DISEASE PATIENTS: A SINGLE-CENTER EXPERIENCE
PO 85  ANOMALOUS AORTIC ORIGIN OF THE RIGHT CORONARY ARTERY: SINGLE CENTRE EXPERIENCE
CO 119  BETABLOCKERS: A MODIFIER OF THE NATURAL HISTORY OF BICUSPID AORTIC VALVES?

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.5 CONGENITAL HEART DISEASE - PREVENTION

CO 118  CARDIOPULMONARY EXERCISE TESTING IN REPAIRED TETRALOGY OF FALLOT AND SUPRAVENTRICULAR ARRYTHMIAS

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.6 CONGENITAL HEART DISEASE - CLINICAL

PO 83  OLD AGE IN ADULT CONGENITAL HEART DISEASE: A CONTEMPORARY REALITY
PO 243  IS NON-VITAMIN K ORAL ANTICOAGULANTS SAFE IN ADULT CONGENITAL HEART DISEASE

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 20. CONGENITAL HEART DISEASE AND PEDIATRIC CARDIOLOGY -> 20.7 PEDIATRIC CARDIOLOGY

CO 137  FOLLOW-UP OF CHILDREN WITH BRUGADA SYNDROME: EXPERIENCE FROM A TERTIARY PAEDIATRIC REFERRAL CENTRE

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE -> 21.2 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 64  DIASTOLIC DISFUNCTION IN PRECAPILLARY PULMONARY HYPERTENSION - LOOKING LEFT TO SEE RIGHT
PO 65  WHAT ARE THE NEWS IN PULMONARY EMBOLISM RISK STRATIFICATION?
PO 160  ECHOCARDIOGRAPHIC DATA IN ACUTE PULMONARY EMBOLISM - WHAT IS THE PROGNOSTIC VALUE IN THE REAL WORLD?
CO 17  COMPERA SCORE REVISED: BETTER RISK ESTIMATION TO BETTER TAILOR THERAPEUTICS IN PRECAPILLARY HYPERTENSION.
CO 19  PULMONARY HYPERTENSION IN CONNECTIVE TISSUE DISEASES WITH OVERT OF FEATURES OF VENOUS/CAPILLARY INVOLVEMENT: CLINICAL IMPLICATIONS AND PROGNOSTIC IMPACT OF THIS PHENOTYPE.
CO 136  RISK STRATIFICATION IN PULMONARY ARTERIAL HYPERTENSION: DO OUR PATIENTS BENEFIT FROM A 4-STRATA MODEL?
CO 138  THORS SCORE, A BETTER PREDICTOR OF IN-HOSPITAL AND LONG-TERM MORTALITY AFTER ACUTE PULMONARY EMBOLISM?

F. VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE -> 21. PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE -> 21.3 PULMONARY CIRCULATION, PULMONARY EMBOLISM, RIGHT HEART FAILURE - DIAGNOSTIC METHODS

PO 157  ELECTROCARDIOGRAPHIC SCORE IN PREDICTING DIAGNOSIS AND SEVERITY OF PULMONARY EMBOLISM
PO 158  COMPARISON OF DIFFERENT DIAGNOSTIC MODELS PERFORMANCE IN PATIENTS WITH COVID-19 AND PULMONARY EMBOLISM
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease

21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure

21.4 Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure - Treatment

- PO 63 Reducing the Risk in Patients with Pulmonary Arterial Hypertension - From Guidelines to Practice
- CO 16 Acute Pulmonary Embolism Catheter-Directed Therapy: First Results of a Multiparametric Follow-Up Protocol
- CO 20 Right Heart Remodeling After Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension
- CO 139 Acute Pulmonary Embolism Catheter-Directed Therapy: A Safety and Feasibility Analysis

21.6 Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure - Clinical

- PO 156 Pulmonary Thromboembolism: Is B-Type Natriuretic Peptide an Earlier Risk Marker?

G. Aortic Disease, Peripheral Vascular Disease, Stroke

22.4 Aortic Disease - Treatment

- PO 239 Early Aortic Valve Replacement in Asymptomatic Severe Aortic Stenosis with Preserved Ejection Fraction
- CO 34 Early Aortic Valve Replacement Versus Conservative Management in Asymptomatic Severe Aortic Stenosis

H. Interventional Cardiology and Cardiovascular Surgery

25. Interventional Cardiology

- PO 24 Could CMV Viremia Have an Impact on Heart Transplant Patients' Hemodynamics?
- CO 45 Ischemic Heart Disease: Looking Beyond Coronary Stenosis

25.2 Coronary Intervention

- PO 112 Residual Syntax Score in TAVR Patients
- PO 114 Radiation in the Cath Lab: Are Patients Really Safe?
- PO 115 Contrast-Induced Nephropathy Following PCI: Can We Calculate a Safe Contrast Volume?
- PO 231 Left Main Artery Lesions: The Role of IVUS and Coronary Physiology
- PO 232 Percutaneous Coronary Intervention in Elderly Patients with Chronic Kidney Disease and Non-ST Segment Elevation Acute Coronary Syndrome - Is it Worth It?
- PO 233 PCI of Chronic Total Occlusions: What is the Clinical Benefit and Impact on Quality of Life?
- PO 234 PCI of Left Main Coronary Artery: Real Life vs Clinical Trials Outcome Results
- PO 235 Stent Strategies in Distal Left Main Lesions: The Simpler, the Better?
- CO 35 Meta-Analysis Comparing Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation with Versus Without Percutaneous Coronary Intervention
- CO 41 A Decade of Experience with Rotational Atherectomy: A Single-Centre Study
H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY -> 25.3 NON-CORONARY CARDIAC INTERVENTION

PO 113 SMALL-BORE ASPIRATION THROMBECTOMY VERSUS CATHETER-DIRECTED THROMBOLYSIS IN INTERMEDIATE-HIGH RISK ACUTE PULMONARY EMBOLISM

PO 152 PERMANENT PACEMAKER IMPLANTATION AFTER ALCOHOLIC SEPTAL ABLATION: LONG-TERM OUTCOMES

PO 153 LEFT ATRIAL APPENDAGE OCCLUSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE OR CANCER: AN INTELLIGENT CHOICE?

PO 154 LEFT ATRIAL APPENDAGE OCCLUSION IS AN EFFECTIVE AND SAFE STRATEGY FOR LONG TERM PREVENTION OF STROKE OR SYSTEMIC EMBOLISM

PO 191 IMPACT OF THE USE OF CUSP OVERLAP PROJECTION TECHNIQUE IN THE INCIDENCE OF POST-TAVR PERMANENT PACEMAKER IMPLANTATION WITH SELF-EXPANDING VALVES

PO 192 PREDICTORS OF FUNCTIONAL RECOVERY AFTER PERCUTANEOUS AORTIC VALVE IMPLANTATION - DATA FROM 459 CASES

PO 193 BLEEDING AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION - WHAT ARE THE OUTCOMES AND HOW CAN WE PREDICT IT

PO 194 IS ILOFEMORAL CALCIUM VOLUME ASSOCIATED WITH VASCULAR AND BLEEDING COMPLICATIONS AFTER TAVI?

PO 236 TRANS-SUBCLAVIAN TRANSCATHETER AORTIC VALVE IMPLANTATION: THE SECOND-LINE ACCESS

PO 237 PERCUTANEOUS TRICUSPID VALVE INTERVENTION - EARLY EXPERIENCE IN A SINGLE CENTRE

PO 238 CLINICAL OUTCOMES OF TRANSARTHEROTOM AORTIC VALVE IMPLANTATION IN YOUNGER PATIENTS

CO 31 VALVE-IN-VALVE TAVI FOR FAILING SURGICAL AORTIC BIOPROSTHETIC VALVES: A SINGLE-CENTRE EXPERIENCE

CO 33 VASCULAR CLOSURE DEVICE IN TAVI WITH A DEDICATED ENDOVASCULAR PLUG-BASED DEVICE. EXPERIENCE FROM A HIGH-VOLUME TERTIARY CENTER

CO 43 PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE: A SINGLE CENTER EXPERIENCE

CO 101 PERCUTANEOUS BALLOON MITRAL VALVULOPLASTY FOR MITRAL STENOSIS PATIENTS: AN OLD BUT RELIABLE WEAPON

CO 102 PREDICTORS OF FUNCTIONAL RECOVERY AFTER MITRAL TRANSCATHETER-EDGE-TO-EDGE REPAIR

CO 103 REFINING PATIENT SELECTION TO PERCUTANEOUS MITRAL VALVE REPAIR IN SECONDARY MITRAL REGURGITATION

CO 104 IMPACT OF RESIDUAL SIGNIFICANT MITRAL REGURGITATION IN TAVR PATIENTS

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 25. INTERVENTIONAL CARDIOLOGY - OTHER

PO 111 BALLOON PULMONARY ANGIOPLASTY IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: WHO BENEFITS THE MOST?

PO 151 PERCUTANEOUS PATENT FORAMEN OVALE CLOSURE: 18 YEARS’ EXPERIENCE IN A TERTIARY CENTRE

PO 155 IS REAL WORLD PATENT FORAMEN OVALE CLOSURE A SAFE AND EFFECTIVE STRATEGY?

PO 195 CONTEMPORARY MANAGEMENT AND OUTCOMES OF PATIENTS WITH VASCULAR COMPLICATIONS DURING TRANSFEMORAL TAVI.

PO 240 BIVALVE: PROCEDURAL AND MID-TERM RESULTS IN PATIENTS WITH AORTIC STENOSIS TREATED WITH IMPLANTATION OF 2 (IN-SERIES) PROSTHESES IN A SINGLE PROCEDURE

CO 32 TRANSCATHETER AORTIC VALVE DESIGN AND MORTALITY: TRUTH OR REALITY?

CO 42 RESIDUAL SHUNT AFTER PATENT FORAMEN OVALE CLOSURE: PREDICTORS’ AND ITS IMPACT ON LONG-TERM OUTCOMES

CO 44 3D PRINTING FOR LEFT ATRIAL APPENDAGE CLOSURE: A META-ANALYSIS OF COHORT STUDIES

CO 105 CAROTID ANGIOPLASTY STENTING VERSUS ENDARTERECTOMY VERSUS BEST MEDICAL TREATMENT - WHAT IS THE BEST STRATEGY FOR THE TREATMENT OF CAROTID STENOSIS?

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY - VALVES

PO 23 MORTALITY PREDICTORS IN INFECTIVE ENDOCARDITIS PATIENTS SUBMITTED TO SURGERY - WHAT CAN BE IMPROVED?
H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.8 CARDIOVASCULAR SURGERY - TRANSPLANTATION

PO 22  QUILTIE EFFECT AND ITS UNCERTAIN REPERCUSSION IN HEART TRANSPLANTED PATIENTS

H. INTERVENTIONAL CARDIOLOGY AND CARDIOVASCULAR SURGERY -> 26. CARDIOVASCULAR SURGERY -> 26.11 CARDIOVASCULAR SURGERY - OTHER

PO 21  POSTSTERNOTOMY MEDIASTINITIS - OUR 10 YEAR EXPERIENCE WITH OMENTUM FLAP SURGERY

I. HYPERTENSION -> 27. HYPERTENSION -> 27.2 HYPERTENSION - EPIDEMIOLOGY, PROGNOSIS, OUTCOME

PO 103  HIGH SALT INTAKE IS A RISK FACTOR FOR KIDNEY FAILURE/MICROALBUMINURIA IN HYPERTENSIVE PATIENTS
PO 105  DOES IT MAKE SENSE TO USE QUESTIONNAIRES TO ASSESS THE CARDIOVASCULAR RISK OF HYPERTENSIVE PATIENTS?

I. HYPERTENSION -> 27. HYPERTENSION -> 27.4 HYPERTENSION - TREATMENT

CO 125  EFFECTS OF HOME-BASED ISOMETRIC HANDGRIP TRAINING IN OLDER ADULTS WITH HIGH BLOOD PRESSURE

I. HYPERTENSION -> 27. HYPERTENSION -> 27.5 HYPERTENSION - PREVENTION

CO 124  SYNERGISM OF TWO ACE GENE VARIANTS IN THE ONSET OF HYPERTENSION IN A PORTUGUESE POPULATION

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.1 RISK FACTORS AND PREVENTION - EPIDEMIOLOGY

CO 24  PROGNOSTIC ROLE OF ADDING A GENETIC RISK SCORE TO THE NEW EUROPEAN SCORE2 IN CARDIOVASCULAR EVENTS PREDICTION, IN A MODERATE-RISK REGION

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.2 RISK FACTORS AND PREVENTION - CARDIOVASCULAR RISK ASSESSMENT

PO 141  CARDIOVASCULAR OUTCOMES ACCORDING TO RISK CATEGORY: RESULTS OF A RETROSPECTIVE DATABASE STUDY
PO 142  DO ATHEROSCLEROTIC EVENTS CHANGE LIPID LOWERING THERAPY USE IN CLINICAL PRACTICE? THE ANSWER WITH RWE
CO 21  POTENTIAL IMPACT OF REPLACING SCORE WITH SCORE-2 ON RISK CLASSIFICATION AND STATIN ELIGIBILITY - A CORONARY CALCIUM SCORE CORRELATION STUDY
CO 22  THE EVALUATION OF THE EUROPEAN SCORE2 IN A PORTUGUESE POPULATION
CO 25  A NEW SCORE MODEL FOR MORTALITY PREDICTION IN TREADMILL TEST

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.3 SECONDARY PREVENTION

CO 74  + CORAÇÃO + VIDA: MAIOR ARTICULAÇÃO E VIGILÂNCIA DO UTENTE COM PATOLOGIA CARDIOVASCULAR E SUAS FAMÍLIAS

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.4 LIPIDS

PO 101  FAMILIAR HYPERCHOLESTEROLEMIA IN ACUTE CORONARY SYNDROME PATIENTS: UNDERDIAGNOSIS IN FEMALE AND IN YOUNG PATIENTS
PO 102  LDL-CHOLESTEROL LEVELS AFTER ACUTE CORONARY SYNDROME: 24-MONTHS VARIATIONS AND IMPACT ON OUTCOMES

PO 104  REAL-WORLD ASSESSMENT OF IPCSK9 TREATMENT ADHERENCE, EFFECTIVENESS, AND TOLERABILITY: A PRELIMINARY ANALYSIS

J. PREVENTIVE CARDIOLOGY -> 28. RISK FACTORS AND PREVENTION -> 28.6 OBESITY

CO 123  IS THE OBESITY PARADOX LEADING TO A LESS STRINGENT SECONDARY PREVENTION STRATEGY IN PATIENTS WHO HAVE SUSTAINED AN ACUTE CORONARY SYNDROME?


PO 143  URIC ACID AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE AND MORTALITY


PO 185  TREADMILL TESTING AND PROGNOSIS: ARE WE LOOKING AT THE RIGHT THINGS?


PO 144  IMPORTANCE OF A GENETIC SCORE IN ASSESSING THE RISK OF ARTERIAL STIFFNESS

PO 145  ANTITHROMBOTIC STRATEGIES AFTER LAA OCCLUSION - IS THERE A WINNING STRATEGY?

CO 23  PROGNOSTIC IMPACT OF ADDING CORONARY CALCIUM SCORE TO EUROPEAN SCORE2 IN AN ASYMPTOMATIC PORTUGUESE POPULATION

J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.1 EXERCISE TESTING

PO 181  EXERCISE TRAINING IMPROVES CARIORESPIRATORY FITNESS IN HEART FAILURE PATIENTS: A LOOK BEYOND PEAK OXYGEN CONSUMPTION

PO 182  VALUE OF CARDIOPULMONARY EXERCISE TEST SUBMAXIMAL PARAMETERS IN THE ASSESSMENT OF AORTIC STENOSIS PATIENTS

J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY -> 29.2 CARDIOVASCULAR REHABILITATION

PO 131  OUTCOMES OF PATIENTS ENROLLED IN A PHASE 2 CARDIAC REHABILITATION PROGRAM ACCORDING TO ACUTE CORONARY SYNDROME

PO 132  CARDIAC REHABILITATION AFTER ELECTIVE HEART SURGERY: A VALVULAR SURGERY FOUSED COMPARISON TO CORONARY ARTERY BYPASS GRAFTING

PO 133  THE RISE OF THE DIGITAL ERA IN CARDIAC REHABILITATION: CAN IT KEEP UP WITH THE PRESENTIAL MODEL?

PO 134  SHORTER CARDIAC REHABILITATION PROGRAMS: TAKING TIME IS TAKING EFFECTIVENESS?

PO 135  CARDIAC REHABILITATION PROGRAMS: DOES SHORTER COURSE TRANSLATE INTO LESS EXERCISE CAPACITY?

PO 183  CARDIAC OPTIMAL POINT: IDENTIFYING HIGH RISK PATIENTS FOR AN OPTIMAL APPROACH

PO 184  VERY ACUTE BENEFITS ON PHYSICAL PERFORMANCE IN ELDERLY PATIENTS WHO UNDERGONE TAVI

CO 121  CARDIAC REHABILITATION AND MUSCLE EFFICIENCY IMPROVEMENT IN HEART FAILURE PATIENTS

CO 122  IMPACT OF CARDIAC REHABILITATION ON INFLAMMATION IN PATIENTS WITH ISCHAEMIC CARDIOMYOPATHY
J. PREVENTIVE CARDIOLOGY -> 29. REHABILITATION AND SPORTS CARDIOLOGY ->
29.4 REHABILITATION AND SPORTS CARDIOLOGY - OTHER
PO 74 EXERCISE TRAINING IN CARDIAC REHABILITATION AND CHANGES IN SELF-REPORTED HEALTH RELATED QUALITY OF LIFE

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.2 CARDIOVASCULAR DISEASE IN WOMEN
PO 15 SEX DISPARITIES IN LIPID-LOWERING THERAPY AND DYSLIPIDEMIC CONTROL IN A CORONARY REHABILITATION PROGRAM

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.3 CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS: PEDIATRIC CARDIOLOGY
PO 227 MYOCARDITIS AND PERICARDITIS FOLLOWING COVID-19 VACCINATION IN ADOLESCENTS
CO 79 CARDIOPULMONARY EXERCISE TESTING IN FONTAN PATIENTS: UNMASKING THE SECRET OF “SUPER-FONTANS”

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.6 CARDIO-ONCOCOLOGY
PO 241 PREDICTORS OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER: A PROSPECTIVE STUDY
CO 76 PREVALENCE OF RV DYSFUNCTION IN PATIENTS UNDER CARDIOTOXIC CHEMOTHERAPY: A PRELIMINARY ANALYSIS
CO 77 CARDIOTOXICITY IN BREAST CANCER PATIENTS - RISK FACTORS AND ROLE OF CARDIOPROTECTIVE DRUGS

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.7 PREGNANCY AND CARDIOVASCULAR DISEASE
CO 73 VASCULAR REMODELLING DURING PREGNANCY AND POSTPARTUM
CO 78 THE IMPACT OF COMORBIDITIES IN CARDIAC REMODELLING AND REVERSE REMODELLING INDUCED BY PREGNANCY

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.9 RENAL FAILURE AND CARDIOVASCULAR DISEASE
PO 11 PERI-PROCEDURAL, 30-DAY AND 1 YEAR-OUTCOMES IN CHRONIC DIALYSIS PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION
PO 14 PREVALENCE AND MANAGEMENT OF CARDIOVASCULAR DISEASE IN PATIENTS WITH PRIOR RENAL TRANSPLANTATION
PO 246 CAD IN KIDNEY TRANSPLANT RECIPIENTS: A REAL-WORLD ASSESSMENT PRE-ISCHEMIA-CKD

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.12 AUTOIMMUNE/CHRONIC INFLAMMATORY DISORDERS AND HEART DISEASE
PO 12 SCREENING PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS USING CARDIOPULMONARY EXERCISE TEST

K. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30. CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS -> 30.14 CARDIOVASCULAR DISEASE IN SPECIAL POPULATIONS - OTHER
PO 13 ACUTE CORONARY SYNDROMES IN YOUNG PEOPLE: APPLICABILITY OF THE GRACE AND CRUSADE SCORES
PO 226 PREDICTORS OF DYSRHYTHMIAS IN COVID-19 INTENSIVE CARE PATIENTS AND IMPACT ON IN-HOSPITAL MORTALITY
M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.1 ACUTE NURSING CARE
PO 71 THE NURSE-FAMILY INTERACTION OF THE CRITICALLY ILL PERSON IN A CARDIAC INTENSIVE CARE UNIT

M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.2 CHRONIC NURSING CARE
CO 75 IMPACTO DA INTERVENÇÃO DO ENFERMEIRO DE REABILITAÇÃO NA REDUÇÃO DOS REINTERNAMENTOS POR INSUFICIÊNCIA CARDIÁCA AOS 30 DIAS

M. CARDIOVASCULAR NURSING -> 32. CARDIOVASCULAR NURSING -> 32.3 CARDIOVASCULAR NURSING - OTHER
PO 72 FUNCTIONAL CAPACITY ASSESSMENT OF ISCHEMIC PATIENTS AFTER ACUTE EVENT USING THE 6MWT
CO 71 PERCEPTION OF NOISE IN A CICU: IMPLICATIONS ON THE WELL-BEING OF PERSON IN CRITICAL SITUATION

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 33. E-CARDIOLOGY / DIGITAL HEALTH -> 33.1 IMAGE PROCESSING AND IMAGING STANDARDS
CO 85 APPLICATION OF ARTIFICIAL INTELLIGENCE IN CORONARY CT ANGIOGRAPHY: A POTENTIAL GATEKEEPER STRATEGY?

N. E-CARDIOLOGY / DIGITAL HEALTH, PUBLIC HEALTH, HEALTH ECONOMICS, RESEARCH METHODOLOGY -> 33. E-CARDIOLOGY / DIGITAL HEALTH -> 33.4 DIGITAL HEALTH
CO 95 DEVELOPMENT OF DEEP LEARNING SEGMENTATION MODELS FOR CORONARY X-RAY ANGIOGRAPHY: PERFORMANCE ASSESSMENT BY NEW CLINICAL CRITERIA SCORE AND COMPARISON WITH HUMAN PERFORMANCE

O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.2 BASIC SCIENCE - CARDIAC BIOLOGY AND PHYSIOLOGY
PO 53 IMPACT OF EXERCISE TRAINING AND CARVEDILOL ON CARDIOVASCULAR PARAMETERS IN DOXORUBICIN TREATED RATS
PO 54 CUMULATIVE DOXORUBICIN DOSAGE IS A TRIGGERING FACTOR FOR COGNITIVE AND PHYSIOLOGICAL DYSFUNCTION?
CO 82 TRANSCRIPTION FACTOR 21 AND PROGNOSIS IN A CAD POPULATION

O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.3 BASIC SCIENCE - CARDIAC DISEASES
PO 52 ZNF 259C>G VARIANT RS964184 IS ASSOCIATED WITH CORONARY ARTERY DISEASE AND DYSLIPIDEMIA IN THE YOUNGER POPULATION
CO 81 HISTOLOGY-VERIFIED MYOCARDIAL FIBROSIS IN SEVERE AS PATIENTS: PREVALENCE AND CORRELATION WITH NON-INVASIVE LV MYOCARDIAL TISSUE ASSESSMENT
CO 84 THERAPEUTIC EFFECT OF UROCORTIN-2 IN HEART FAILURE WITH PRESERVED EJECTION FRACTION
O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.5 BASIC SCIENCE - VASCULAR DISEASES

PO 51 THERAPEUTIC EFFECTS OF NEBULIZATION- BASED DELIVERY OF ANTI-MIR-146A IN EXPERIMENTAL PULMONARY ARTERIAL HYPERTENSION

PO 55 PULMONARY EMBOLISM - PLATELET INDICES’ IN PATIENTS WITH OR WITHOUT RIGHT VENTRICULAR DILATATION

O. BASIC SCIENCE -> 36. BASIC SCIENCE -> 36.6 BASIC SCIENCE - OTHER

CO 83 PLASMA LIPIDOMICS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION

P. OTHER -> 37. MISCELLANEA

PO 31 PREDICTING THE LONG-TERM OUTCOME OF PATIENTS ADMITTED WITH ACUTE HEART FAILURE TO THE EMERGENCY DEPARTMENT USING RENAL MARKERS